EPHX2 and ischemia: Given the lack of available therapies to minimize reperfusion injury, potential treatment options could involve increasing levels of oxylipins derived from docosahexaenoic acid (DHA), such as 17-Keto DHA and 17-Keto DPA, as well as inhibiting the soluble epoxide hydrolysis (sEH) enzyme during ischemia or early after reperfusion.